MENLO PARK, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that the company will be participating in and hosting 1x1 investor meetings at the following September conferences:

• Rodman & Renshaw 19th Annual Global Investment Conference - Peter Staple, Corium's Chairman and Chief Executive Officer, will present in New York City on Monday, September 11, 2017 at 4:40 - 5:05 pm Eastern time.  A live webcast of Corium's presentation may be accessed here.
   
• Mizuho Securities CNS "Deep Management" Day - The Corium management team will be hosting 1x1 meetings on Tuesday, September 19, 2017 in Boston.
   
• Cantor Fitzgerald's 2017 Healthcare Conference - Mr. Staple will present in New York City on Tuesday, September 26, 2017 at 9:10 am Eastern time.  A live webcast of Corium's presentation may be accessed here.

The webcasts and presentations can also be accessed by visiting "Events & Presentations" in the Investors section of the Company's website at www.coriumgroup.com.  They will be archived on the Corium website for two weeks following the presentations.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems.  Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease.  Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble.  The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor^®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.  In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners.  For further information, please visit www.coriumintl.com.

Corplex™ and MicroCor^® are registered trademarks of Corium International, Inc.

Source: Corium

Investor and Media Contact:

SMP CommunicationsSusan M. Pietropaolosusan@smpcommunications.com

(201) 923-2049

News Provided by Acquire Media